Breaking: GW Pharma Confirms No Epidiolex Supply Issues

A post on Twitter today has pressured GW Pharma (NASDAQ: GWPH), which dipped more than 3% to $145.21. The post, by Ryan Flinn, a Bay Area journalist in healthcare public relations, indicated that he was having trouble procuring Epidiolex, recently approved for treating seizures caused by epilepsy:

Seeking Alpha published a headline to a short summary indicating that the company may be “facing supply issues”.

We reached out to company spokesperson Steve Schultz, who responded that “We have no supply issue whatsoever.” Schultz was familiar with the tweet but was not aware of the particular details.  He explained that the company has seen some issues with insurance companies, and he indicated that specialty pharmacies are providing dosing only in line with what has been prescribed by the doctor.

GW Pharma is scheduled to report financial results for the quarter ending December 31 later this month.

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Breaking News by Alan Brochstein, CFA
Alan Brochstein, CFA
Based in Houston, Alan leverages his experience as founder of online communities 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email

Get Our Sunday Newsletter